DMAC · Nasdaq · CIK 0001401040

DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc.’s most recent SEC filing in our snapshot is a Form 4 filed on Aug 12, 2026. Its EDGAR record lists 16 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$32.8M
Form 4 filings on record, past 12 months
16

Company overview

Legal name (as filed)
DiaMedica Therapeutics Inc.
Ticker
DMAC
SEC Central Index Key (CIK)
0001401040
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
MINNEAPOLIS, MN
State or country of incorporation
Canada (Federal Level)
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#2955 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from DiaMedica Therapeutics Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022n/aFY2023n/aFY2024n/aFY2025
Net income
-$13.6MFY2021-$13.7MFY2022-$19.4MFY2023-$24.4MFY2024-$32.8MFY2025
DMAC annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—————
Net income-$13.6M-$13.7M-$19.4M-$24.4M-$32.8M
Diluted EPS-$0.65————
Total assets$45.6M$34.4M$54.2M$46.3M$61.4M
Cash and equivalents$4.7M$4.7M$4.5M$3.0M$15.6M

XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareBasicAndDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

DMAC latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 30, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 10, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 10, 20268-KResults of operations· period Aug 10, 2026Document · Index
Apr 1, 2026DEF 14ADefinitive proxy statement· period May 20, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about DiaMedica Therapeutics Inc., by form type:

4 ×178-K ×7SCHEDULE 13G/A ×610-Q ×3S-8 ×23 ×1ARS ×1DEFA14A ×1DEF 14A ×110-K ×1
DMAC recent filings
FiledFormWhat it isOriginal
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 11, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Aug 10, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 10, 20268-KResults of operations· period Aug 10, 2026Document · Index
Jun 3, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
Jun 3, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
Jun 3, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
Jun 3, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
Jun 3, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
Jun 3, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
Jun 3, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
Jun 3, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
Jun 3, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
May 21, 20268-KShareholder vote results· period May 20, 2026Document · Index
May 6, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 6, 20268-KResults of operations· period May 6, 2026Document · Index
Apr 1, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 1, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 1, 2026DEF 14ADefinitive proxy statement· period May 20, 2026Document · Index
Mar 31, 20268-KResults of operations· period Mar 30, 2026Document · Index
Mar 30, 202610-KAnnual report· period Dec 31, 2025Document · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 6, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jan 6, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 2, 2026Document · Index
Jan 6, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 2, 2026Document · Index
Jan 6, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 2, 2026Document · Index
Jan 5, 20268-KOther events· period Jan 5, 2026Document · Index
Dec 18, 20258-KRegulation FD disclosure; Other events· period Dec 18, 2025Document · Index
Dec 8, 20254Statement of changes in beneficial ownership (insider trade)· period Nov 17, 2025Document · Index
Nov 25, 20254Statement of changes in beneficial ownership (insider trade)· period Nov 21, 2025Document · Index
Nov 13, 2025S-8Registration of employee benefit plan securitiesDocument · Index
Nov 12, 202510-QQuarterly report· period Sep 30, 2025Document · Index
Nov 12, 20258-KResults of operations· period Nov 12, 2025Document · Index
Nov 7, 2025SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Nov 3, 20254Statement of changes in beneficial ownership (insider trade)· period Aug 11, 2025Document · Index
Nov 3, 20253Initial statement of beneficial ownership· period Aug 11, 2025Document · Index
Oct 15, 2025SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Sep 4, 20254Statement of changes in beneficial ownership (insider trade)· period Aug 13, 2025Document · Index
Sep 4, 2025SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index

Insider filing activity

16 Form 4 filings appear in DiaMedica Therapeutics Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in Minnesota

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001401040 and XBRL company facts. DiaMedica Therapeutics Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.